• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

间充质干细胞的抗原呈递特性在低水平干扰素-γ的狭窄窗口期出现。

Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma.

作者信息

Chan Jennifer L, Tang Katherine C, Patel Anoop P, Bonilla Larissa M, Pierobon Nicola, Ponzio Nicholas M, Rameshwar Pranela

机构信息

Department of Pharmacology and Physiology, New Jersey Medical School-University of Medicine and Dentistry of New Jersey, Newark, NJ 07103, USA.

出版信息

Blood. 2006 Jun 15;107(12):4817-24. doi: 10.1182/blood-2006-01-0057. Epub 2006 Feb 21.

DOI:10.1182/blood-2006-01-0057
PMID:16493000
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1895812/
Abstract

Mesenchymal stem cells (MSCs) are mostly found around the vasculature system of the adult bone marrow (BM). They function as immune suppressors, express MHC-II, are phagocytic, and support T-cell cytotoxicity. We hypothesize that these contradictory properties of MSCs are important for BM homeostasis and occur partly through antigen presentation (antigen-presenting cells [APCs]) within a narrow window. Indeed, we have verified APC functions of MSCs to recall antigens, Candida albicans and Tetanus toxoid. The target cells have been identified to be CD4(+) T cells. APC assays with IFNgamma-knockdown MSCs and with anti-IFNgamma receptor confirmed that MHC-II expression requires autocrine stimulation by IFNgamma. During APC functions, as IFNgamma levels become elevated, there was a concomitant decrease in MHC-II on MSCs. This observation was correlated with flow cytometry studies showing a gradual decrease in MHC-II expression as IFNgamma levels were increased. The reduced levels of MHC-II correlated with losses in their allogeneic potential, as indicated in mixed lymphocyte reaction. In summary, endogenous and low levels of IFNgamma are required for MHC-II expression on MSCs, and for APC functions. APC functions occur during a narrow window before IFNgamma levels are increased. The study has implications for BM protection against infection and exacerbated inflammatory responses.

摘要

间充质干细胞(MSCs)大多存在于成人骨髓(BM)的脉管系统周围。它们发挥免疫抑制作用,表达MHC-II,具有吞噬作用,并支持T细胞的细胞毒性。我们推测,MSCs的这些相互矛盾的特性对骨髓稳态很重要,并且部分是通过在一个狭窄窗口期内的抗原呈递(抗原呈递细胞[APC])来实现的。事实上,我们已经证实了MSCs作为APC回忆抗原(白色念珠菌和破伤风类毒素)的功能。已确定靶细胞为CD4(+) T细胞。用IFNγ敲低的MSCs和抗IFNγ受体进行的APC检测证实,MHC-II的表达需要IFNγ的自分泌刺激。在APC功能过程中,随着IFNγ水平升高,MSCs上的MHC-II随之减少。这一观察结果与流式细胞术研究相关,该研究表明随着IFNγ水平升高,MHC-II表达逐渐降低。MHC-II水平降低与混合淋巴细胞反应中显示的其同种异体潜力丧失相关。总之,MSCs上MHC-II的表达以及APC功能需要内源性和低水平的IFNγ。APC功能在IFNγ水平升高之前的一个狭窄窗口期内发生。该研究对骨髓抗感染和减轻炎症反应具有重要意义。

相似文献

1
Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma.间充质干细胞的抗原呈递特性在低水平干扰素-γ的狭窄窗口期出现。
Blood. 2006 Jun 15;107(12):4817-24. doi: 10.1182/blood-2006-01-0057. Epub 2006 Feb 21.
2
Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation.恶性神经胶质瘤细胞利用MHC II类反式激活因子(CIITA)启动子III和IV来指导干扰素-γ诱导的CIITA表达,并可在内吞加工和CD4(+) T细胞激活中作为非专职抗原呈递细胞发挥作用。
Glia. 2001 Dec;36(3):391-405. doi: 10.1002/glia.1125.
3
Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell.干扰素-γ刺激的骨髓基质细胞:一种新型的非造血抗原呈递细胞。
Blood. 2006 Mar 15;107(6):2570-7. doi: 10.1182/blood-2005-07-2793. Epub 2005 Nov 17.
4
Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition.II类主要组织相容性复合体/肽复合物从抗原呈递细胞释放,并在特异性抗原识别过程中被T细胞应答者获得。
J Immunol. 1999 Nov 15;163(10):5201-10.
5
IFNγ-Induced MHC Class II Expression on Islet Endothelial Cells Is an Early Marker of Insulitis but Is Not Required for Diabetogenic CD4 T Cell Migration.IFNγ 诱导胰岛内皮细胞 MHC Ⅱ类分子的表达是胰岛炎的早期标志物,但对于致糖尿病性 CD4 T 细胞的迁移并非必需。
Front Immunol. 2018 Nov 28;9:2800. doi: 10.3389/fimmu.2018.02800. eCollection 2018.
6
Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties.间充质基质细胞作为其抗原呈递细胞特性的一部分,交叉呈递可溶性外源性抗原。
Blood. 2009 Sep 24;114(13):2632-8. doi: 10.1182/blood-2009-02-207795. Epub 2009 Aug 4.
7
Antigen presentation and MHC class II expression by human esophageal epithelial cells: role in eosinophilic esophagitis.人食管上皮细胞的抗原呈递和 MHC Ⅱ类分子表达:在嗜酸性食管炎中的作用。
Am J Pathol. 2011 Feb;178(2):744-53. doi: 10.1016/j.ajpath.2010.10.027.
8
The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.MHC II类癌症疫苗中恒定链的缺失增强了肿瘤反应性1型CD4+T淋巴细胞的激活。
Cancer Immunol Immunother. 2008 Mar;57(3):389-98. doi: 10.1007/s00262-007-0381-5. Epub 2007 Aug 28.
9
Class II MHC antigen processing in immune tolerance and inflammation.Ⅱ类 MHC 抗原加工在免疫耐受和炎症中的作用。
Immunogenetics. 2019 Mar;71(3):171-187. doi: 10.1007/s00251-018-1095-x. Epub 2018 Nov 12.
10
Down-regulation of MHC II in mesenchymal stem cells at high IFN-gamma can be partly explained by cytoplasmic retention of CIITA.在高浓度干扰素-γ作用下,间充质干细胞中MHC II的下调部分可由CIITA的胞质滞留来解释。
J Immunol. 2008 Feb 1;180(3):1826-33. doi: 10.4049/jimmunol.180.3.1826.

引用本文的文献

1
Mesenchymal stromal cells 2.0: thinking outside the box.间充质基质细胞2.0:跳出框框思考。
Front Immunol. 2025 Aug 20;16:1657048. doi: 10.3389/fimmu.2025.1657048. eCollection 2025.
2
ARM-X: an adaptable mesenchymal stromal cell-based vaccination platform suitable for solid tumors.ARM-X:一种适用于实体瘤的基于间充质基质细胞的适应性疫苗接种平台。
Stem Cell Res Ther. 2025 Jul 15;16(1):369. doi: 10.1186/s13287-025-04465-5.
3
Pooling umbilical cord-mesenchymal stromal cells derived from selected multiple donors reduces donor-dependent variability and improves their immunomodulatory properties.汇集来自多个选定供体的脐带间充质基质细胞可降低供体依赖性变异性并改善其免疫调节特性。
Stem Cell Res Ther. 2025 May 20;16(1):252. doi: 10.1186/s13287-025-04361-y.
4
Mesenchymal Stem Cells with Simultaneous Overexpression of GPX3 and CD47 for the Treatment of Drug-Induced Acute Liver Injury.同时过表达GPX3和CD47的间充质干细胞用于治疗药物性急性肝损伤
Vet Sci. 2025 Feb 10;12(2):149. doi: 10.3390/vetsci12020149.
5
Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Autoimmune Diseases.基于间充质基质细胞的疗法:一种治疗自身免疫性疾病的有前景的方法。
Clin Rev Allergy Immunol. 2025 Feb 21;68(1):21. doi: 10.1007/s12016-025-09030-9.
6
Proteomic profiling of iPSC and tissue-derived MSC secretomes reveal a global signature of inflammatory licensing.诱导多能干细胞和组织来源间充质干细胞分泌组的蛋白质组学分析揭示了炎症许可的整体特征。
NPJ Regen Med. 2025 Feb 4;10(1):7. doi: 10.1038/s41536-024-00382-y.
7
Fate and long-lasting therapeutic effects of mesenchymal stromal/stem-like cells: mechanistic insights.间充质基质/干细胞样细胞的命运及长期治疗效果:机制洞察
Stem Cell Res Ther. 2025 Feb 4;16(1):33. doi: 10.1186/s13287-025-04158-z.
8
Increasing robustness of assay for immnosuppressive effect of mesenchymal stromal/stem cells: The role of inflammatory cytokine production by peripheral blood mononuclear cells.增强间充质基质/干细胞免疫抑制作用检测的稳健性:外周血单个核细胞产生炎性细胞因子的作用
Regen Ther. 2025 Jan 9;28:321-332. doi: 10.1016/j.reth.2024.12.016. eCollection 2025 Mar.
9
In situ licensing of mesenchymal stem cell immunomodulatory function via BMP-2 induced developmental process.通过 BMP-2 诱导的发育过程原位赋予间充质干细胞免疫调节功能。
Proc Natl Acad Sci U S A. 2024 Nov 26;121(48):e2410579121. doi: 10.1073/pnas.2410579121. Epub 2024 Nov 20.
10
The Role of Mesenchymal Stem Cells in Modulating Adaptive Immune Responses in Multiple Sclerosis.间充质干细胞在多发性硬化症中调节适应性免疫反应的作用。
Cells. 2024 Sep 16;13(18):1556. doi: 10.3390/cells13181556.

本文引用的文献

1
Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell.干扰素-γ刺激的骨髓基质细胞:一种新型的非造血抗原呈递细胞。
Blood. 2006 Mar 15;107(6):2570-7. doi: 10.1182/blood-2005-07-2793. Epub 2005 Nov 17.
2
Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement.间充质干细胞命名的澄清:国际细胞治疗协会立场声明
Cytotherapy. 2005;7(5):393-5. doi: 10.1080/14653240500319234.
3
First experience of the use bone marrow mesenchymal stem cells for the treatment of a patient with deep skin burns.使用骨髓间充质干细胞治疗一名深度皮肤烧伤患者的首次经验。
Bull Exp Biol Med. 2005 Jan;139(1):141-4. doi: 10.1007/s10517-005-0232-3.
4
Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles.干扰素-γ诱导的CD34细胞基因表达:病理性细胞因子特异性特征谱的鉴定
Blood. 2006 Jan 1;107(1):167-75. doi: 10.1182/blood-2005-05-1884. Epub 2005 Aug 30.
5
Prospective monitoring of tumor necrosis factor alpha and interferon gamma to predict the onset of acute and chronic graft-versus-host disease after allogeneic stem cell transplantation.前瞻性监测肿瘤坏死因子α和干扰素γ以预测异基因干细胞移植后急性和慢性移植物抗宿主病的发生。
Biol Blood Marrow Transplant. 2005 Sep;11(9):706-12. doi: 10.1016/j.bbmt.2005.05.015.
6
Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice.同种异体骨髓基质细胞会被主要组织相容性复合体I类和II类不匹配的受体小鼠免疫排斥。
Blood. 2005 Dec 15;106(13):4057-65. doi: 10.1182/blood-2005-03-1004. Epub 2005 Aug 23.
7
T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia.间充质干细胞介导的T细胞抑制在重型再生障碍性贫血患者中存在缺陷。
Exp Hematol. 2005 Jul;33(7):819-27. doi: 10.1016/j.exphem.2005.05.006.
8
A paradoxical role for IFN-gamma in the immune properties of mesenchymal stem cells during viral challenge.γ干扰素在病毒攻击期间间充质干细胞免疫特性中的矛盾作用。
Exp Hematol. 2005 Jul;33(7):796-803. doi: 10.1016/j.exphem.2005.03.012.
9
Neurons derived from human mesenchymal stem cells show synaptic transmission and can be induced to produce the neurotransmitter substance P by interleukin-1 alpha.源自人间充质干细胞的神经元表现出突触传递,并且可被白细胞介素-1α诱导产生神经递质P物质。
Stem Cells. 2005 Mar;23(3):383-91. doi: 10.1634/stemcells.2004-0251.
10
Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro.骨髓增生异常综合征患者产生的间充质细胞缺乏染色体克隆标记,并且在体外支持短期和长期造血。
Oncogene. 2005 Apr 7;24(15):2441-8. doi: 10.1038/sj.onc.1208405.